Europe resumes using AstraZeneca shots as France introduces new locks

The European Medicines Agency said in a much-anticipated report on Thursday that the benefits of the AstraZeneca COVID-19 vaccine “outweigh the risk of side effects” and that the bullet is “unrelated”. to increase the overall risk of blood clots. ”

  • Distribution of the vaccine will now begin in Germany, France, Italy, Spain and most other EU countries that have stopped using the image pending the investigation. EMA. But Sweden and Denmark, as well as Norway (outside the EU), said they needed more time to review the report.

  • The EMA stated that “the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia,” but noted that a causal link to the vaccine has not been established, but that it is possible and worthy of further analysis. ”

  • The French government announced on Thursday that the greater Paris area will be locked up, forcing President Emmanuel Macron to back down, believing that such austerity measures could be avoided.

  • The pandemic is spreading in France, and the Paris region is the third largest French region ordered back to lockdown after the Pas de Calais in the north and the entire Riviera region in the south.

Read: EU regulator calls AstraZeneca vaccine ‘safe’ after blood clot examination

The preview: Even just a few days of shutdown of the AstraZeneca AZN,
Vaccination has further delayed Europe’s troubled vaccination campaigns, which are now able to resume. Although the UK has been able to vaccinate 40% of its population, that proportion is only 12% in the EU.

At the same time, Macron may have to pay a heavy political price for looking back on claims that France could avoid the tight locks that went through last year. With around a third of France’s territory – and most populated areas – now under the harshest regime, it will be a disappointment to both the impatient opponents of restrictions and those who was careful to warn that his policies were dangerous.

Read: Why tightening vaccine supply is unlikely to be under control